Tubize-Fin (TUB) - Total Liabilities
Based on the latest financial reports, Tubize-Fin (TUB) has total liabilities worth €48.58 Million EUR (≈ $56.79 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TUB cash flow metrics to assess how effectively this company generates cash.
Tubize-Fin - Total Liabilities Trend (2000–2025)
This chart illustrates how Tubize-Fin's total liabilities have evolved over time, based on quarterly financial data. Check Tubize-Fin liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Tubize-Fin Competitors by Total Liabilities
The table below lists competitors of Tubize-Fin ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CCL Industries Inc
TO:CCL-B
|
Canada | CA$4.92 Billion |
|
Shanghai International Airport Co Ltd
SHG:600009
|
China | CN¥25.68 Billion |
|
Biomerieux SA
PA:BIM
|
France | €1.43 Billion |
|
Xero Ltd
AU:XRO
|
Australia | AU$2.09 Billion |
|
Viavi Solutions Inc
NASDAQ:VIAV
|
USA | $1.94 Billion |
|
Smithfield Foods, Inc. Common Stock
NASDAQ:SFD
|
USA | $4.80 Billion |
|
BIM Birlesik Magazalar AS
IS:BIMAS
|
Turkey | TL173.20 Billion |
|
Anker Innovations Technology Co Ltd
SHE:300866
|
China | CN¥9.91 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Tubize-Fin's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TUB market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tubize-Fin's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tubize-Fin (2000–2025)
The table below shows the annual total liabilities of Tubize-Fin from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €48.58 Million ≈ $56.79 Million |
-45.59% |
| 2024-12-31 | €89.28 Million ≈ $104.37 Million |
-27.80% |
| 2023-12-31 | €123.65 Million ≈ $144.56 Million |
+41.82% |
| 2022-12-31 | €87.19 Million ≈ $101.93 Million |
+316.40% |
| 2021-12-31 | €20.94 Million ≈ $24.48 Million |
-38.88% |
| 2020-12-31 | €34.26 Million ≈ $40.05 Million |
-60.83% |
| 2019-12-31 | €87.46 Million ≈ $102.25 Million |
-39.28% |
| 2018-12-31 | €144.04 Million ≈ $168.40 Million |
-26.38% |
| 2017-12-31 | €195.65 Million ≈ $228.74 Million |
-26.24% |
| 2016-12-31 | €265.26 Million ≈ $310.12 Million |
-14.94% |
| 2015-12-31 | €311.84 Million ≈ $364.57 Million |
+46.03% |
| 2014-12-31 | €213.55 Million ≈ $249.66 Million |
-15.67% |
| 2013-12-31 | €253.23 Million ≈ $296.05 Million |
-13.73% |
| 2012-12-31 | €293.53 Million ≈ $343.17 Million |
-8.36% |
| 2011-12-31 | €320.31 Million ≈ $374.48 Million |
-6.06% |
| 2010-12-31 | €340.97 Million ≈ $398.63 Million |
-7.00% |
| 2009-12-31 | €366.64 Million ≈ $428.64 Million |
-5.97% |
| 2008-12-31 | €389.92 Million ≈ $455.86 Million |
-5.77% |
| 2007-12-31 | €413.79 Million ≈ $483.77 Million |
+72.19% |
| 2006-12-31 | €240.31 Million ≈ $280.95 Million |
+104.48% |
| 2005-12-31 | €117.52 Million ≈ $137.40 Million |
-4.22% |
| 2004-12-31 | €122.70 Million ≈ $143.44 Million |
-21.41% |
| 2003-12-31 | €156.12 Million ≈ $182.52 Million |
-8.94% |
| 2002-12-31 | €171.45 Million ≈ $200.44 Million |
+33.07% |
| 2001-12-31 | €128.84 Million ≈ $150.63 Million |
+57.37% |
| 2000-12-31 | €81.87 Million ≈ $95.72 Million |
-- |
About Tubize-Fin
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. It engages in discovering and developing treatments for patients suffering from serious illnesses that affect the immune system or the central nervous system. The company was incorporated in 1928 and is based in Brussels, Belgium.